# QV Bioelectronics

Developing innovative electrotherapies for cancer

| | |
|---|---|
| Area | Treatment |
| Headquarter | Manchester, UK |
| Countries of operation | UK |
| Founding year | 2018 |
| Status | Prototype |

Glioblastoma (GBM) is the most common primary adult brain cancer and also has amongst the worst outcomes of any type of cancer; there is no cure and life expectancy is just 14 months post-diagnosis with current standard of care.
Fortunately, there are new electrotherapy approaches to treating these cancers - using electrical fields applied at specific frequencies to interfere with cancer cell division slowing the growth of tumours and extending the lives of patients. An existing externally applied lectrotherapy device has been shown to extend the lives of GBM patients by almost 50% but comes at a huge cost to the quality of life of the patients.
QV Bioelectronics is developing an implanted device that will overcome these quality of life issues whilst also increasing treatment efficacy.

| | |
|---|---|
| Incubator programme | RebelBio, North of England Life Sciences Accelerator |
| Approvals | Class III active implantable device approval |
| Awards | Britt and Eli Harari Award |
| Patents | N/A |
| Revenue (last yr) | N/A |
| Funds raised | £100k equity over £225k non-dilutive |
| Currently raising: | £ 2.6 M |

Current investors SOSV will contribute 20% of the round.




## Interested? Get in touch

greg@clab.ventures

www.QVBio.co.uk